Ciclesonide Nasal — Membership Pricing

Other medications in Allergy & Immunology

• Fexofenadine
• Ipratropium Nasal
• Loratadine
• Oxymetazoline Nasal
• Azelastine Nasal
• Cetirizine

About Ciclesonide Nasal

Ciclesonide nasal is a widely prescribed corticosteroid spray used to relieve symptoms of allergic rhinitis, such as congestion and sneezing. For many, managing these chronic conditions can be costly. TheDrugClub is dedicated to helping members access their necessary medications, including ciclesonide nasal, at more affordable prices, ensuring you can prioritize your health without financial strain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ciclesonide Nasal is approved for (FDA label)

OMNARIS Nasal Spray is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older. ( 1.1 , 1.2 ) 1.1 Treatment of Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 1.2 Treatment of Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: November 8, 2022.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ciclesonide Nasal (FDA label)

OMNARIS Nasal Spray is a metered-dose, manual-pump spray formulation containing a hypotonic aqueous suspension of ciclesonide. Once primed, each actuation of the pump delivers 50 mcg ciclesonide in a volume of 70 microliters from the nasal actuator. Nasal Spray: 50 mcg of ciclesonide in each 70-microliter spray. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 15fefd46-ac7e-40d0-b635-e6c3d653c666. SPL document ID: fa248cfa-08c9-43a3-8289-a28e5447cb1d. Label effective date: November 8, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ciclesonide Nasal (FDA label)

Systemic and local corticosteroid use may result in the following: • Epistaxis, nasal septal perforations, Candida albicans infection, impaired wound healing [see Warnings and Precautions ( 5.1 )] • Cataracts and glaucoma [see Warnings and Precautions ( 5.2 )] • Immunosuppression [see Warnings and Precautions ( 5.3 )] • Hypothalamic-pituitary-adrenal (HPA) axis effects, including growth reduction [see Warnings and Precautions ( 5.4 , 5.5 ), Use in Specific Populations ( 8.4 )] The most common adverse reactions (>2% incidence) included headache, epistaxis, nasopharyngitis, ear pain, and pharyngolaryngeal pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 1-866-488-4423 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 15fefd46-ac7e-40d0-b635-e6c3d653c666. SPL document ID: fa248cfa-08c9-43a3-8289-a28e5447cb1d. Label effective date: November 8, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ciclesonide Nasal (FDA label)

OMNARIS Nasal Spray is contraindicated in patients with a known hypersensitivity to ciclesonide or any of the ingredients of OMNARIS Nasal Spray [see Warnings and Precautions ( 5.3 )] . Patients with a known hypersensitivity to ciclesonide or any of the ingredients of OMNARIS Nasal Spray. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 15fefd46-ac7e-40d0-b635-e6c3d653c666. SPL document ID: fa248cfa-08c9-43a3-8289-a28e5447cb1d. Label effective date: November 8, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ciclesonide Nasal (FDA label)

• Epistaxis, Candida albicans infection, nasal septal perforation, impaired wound healing. Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid spraying OMNARIS directly onto the nasal septum. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma. ( 5.1 ) • Development of glaucoma or cataracts. Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts. ( 5.2 ) • Potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections. ( 5.3 ) • Hypercorticism and adrenal suppression with very high dosages or at the regular dosage in susceptible individuals.

Source: FDA prescribing information (DailyMed). Set ID: 15fefd46-ac7e-40d0-b635-e6c3d653c666. SPL document ID: fa248cfa-08c9-43a3-8289-a28e5447cb1d. Label effective date: November 8, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ciclesonide Nasal (FDA label)

In vitro studies and clinical pharmacology studies suggested that des-ciclesonide has no potential for metabolic drug interactions or protein binding-based drug interactions [see Clinical Pharmacology ( 12.3 )] . In a drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. Erythromycin, a moderate inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin following oral inhalation of ciclesonide [see Clinical Pharmacology ( 12.3 )] .

Source: FDA prescribing information (DailyMed). Set ID: 15fefd46-ac7e-40d0-b635-e6c3d653c666. SPL document ID: fa248cfa-08c9-43a3-8289-a28e5447cb1d. Label effective date: November 8, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.